Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers

Introduction: analyze characteristics and survival depending on different molecular markers in NSCLC stage IV Material and Methods: Retrospective study of all cases diagnosed of NSCLC stage IV at UH. Cruces from 1/1/2015 to 31/12/2017. We have studied:sociodemographics, ECOG, molecular markers (EGFR, pdl-1, ALK, BRAF and ROS), treatment received and mortality, using COX regression and Kaplan-Meier curves Results: 278 patients, mean age 65.3,74.8% male.11.5% never smokers.196(70.5%) adenocarcinomas,44(15.8%)squamous cell carcinoma and 38(13.7%) large-cell and other types. Molecular markers were studied in 242(87.1%):196(81%) negative,24(9.9%) mutated EGFR, 25(10.3%)with expression of pdl-1 ≥50%,3 positive ALK,3 BRAF and 0 ROS. Of 24 mutated EGFR,15 deletion of exon 19. In the expression of pdl-1, no differences by gender, tobacco or histology.41.7% were treated symptomatically,49.3% usual chemotherapy and 9% targeted therapy according to markers. Survival 6.34 months. Patients with molecular mutations lived longer(8.07 months)than non-mutated patients (6.5)(p=0.029). No difference in survival depending on pdl-1 Conclusions: EGFR mutated in 10%, mostly in women and non-smokers, all of them adenocarcinoma. Low prevalence of the other mutations. Mutation of EGFR has better prognosis. In the multivariate analysis, the IVA vs IVB stage, ECOG, RT and treatment with ITK in mutated EGFR leads to a better prognosis.